SrasV1, Ncbi, Merge, bibRecord, 002048

Annexin A2 on lung epithelial cell surface is recognized by severe acute respiratory syndrome-associated coronavirus spike domain 2 antibodies.

Identifieur interne : 002048 ( Ncbi/Merge ); précédent : 002047; suivant : 002049

Annexin A2 on lung epithelial cell surface is recognized by severe acute respiratory syndrome-associated coronavirus spike domain 2 antibodies.

Auteurs : Yi-Ting Fang [Taïwan] ; Chiou-Feng Lin ; Pao-Chi Liao ; Yu-Min Kuo ; Shuying Wang ; Trai-Ming Yeh ; Chi-Chang K. Shieh ; Ih-Jen Su ; Huan-Yao Lei ; Yee-Shin Lin

Source :

Molecular immunology [ 1872-9142 ] ; 2010.

RBID : pubmed:20015551

Descripteurs français

English descriptors

KwdEn :
- Annexin A2 (immunology), Antibodies, Viral (immunology), Antiviral Agents (pharmacology), Autoantigens (immunology), Cell Line, Tumor, Cross Reactions (immunology), Epithelial Cells (immunology), Epithelial Cells (pathology), Epithelial Cells (virology), Humans, Interferon-gamma (pharmacology), Interleukin-6 (pharmacology), Membrane Glycoproteins (immunology), Protein Structure, Tertiary, Respiratory Mucosa (immunology), Respiratory Mucosa (pathology), Respiratory Mucosa (virology), SARS Virus (immunology), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (pathology), Severe Acute Respiratory Syndrome (virology), Spike Glycoprotein, Coronavirus, Up-Regulation (drug effects), Up-Regulation (immunology), Viral Envelope Proteins (immunology).
MESH :
- chemical , immunology : Annexin A2, Antibodies, Viral, Autoantigens, Membrane Glycoproteins, Viral Envelope Proteins.
- chemical , pharmacology : Antiviral Agents, Interferon-gamma, Interleukin-6.
- drug effects : Up-Regulation.
- immunology : Cross Reactions, Epithelial Cells, Respiratory Mucosa, SARS Virus, Severe Acute Respiratory Syndrome, Up-Regulation.
- pathology : Epithelial Cells, Respiratory Mucosa, Severe Acute Respiratory Syndrome.
- virology : Epithelial Cells, Respiratory Mucosa, Severe Acute Respiratory Syndrome.
- Cell Line, Tumor, Humans, Protein Structure, Tertiary, Spike Glycoprotein, Coronavirus.

Abstract

Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infection causes lung failure characterized by atypical pneumonia. We previously showed that antibodies against SARS-CoV spike domain 2 (S2) in the patient sera can cross-react with human lung epithelial cells; however, the autoantigen is not yet identified. In this study, we performed proteomic studies and identified several candidate autoantigens recognized by SARS patient sera in human lung type II epithelial cell A549. Among the candidate proteins, annexin A2, which was identified by mass spectrometry analysis and had the highest score by Mascot data search, was further characterized and investigated for its role as an autoantigen. By confocal microscopic observation, SARS patient sera and anti-S2 antibodies were co-localized on A549 cells and both of them were co-localized with anti-annexin A2 antibodies. Anti-annexin A2 antibodies bound to purified S2 proteins, and anti-S2 bound to immunoprecipitated annexin A2 from A549 cell lysate in a dose-dependent manner. Furthermore, an increased surface expression and raft-structure distribution of annexin A2 was present in A549 cells after stimulation with SARS-induced cytokines interleukin-6 and interferon-gamma. Cytokine stimulation increased the binding capability of anti-S2 antibodies to human lung epithelial cells. Together, the upregulated expression of annexin A2 by SARS-associated cytokines and the cross-reactivity of anti-SARS-CoV S2 antibodies to annexin A2 may have implications in SARS disease pathogenesis.

DOI: 10.1016/j.molimm.2009.11.019
PubMed: 20015551

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 001780
to stream PubMed, to step Curation: 001780
to stream PubMed, to step Checkpoint: 001714

Links to Exploration step

pubmed:20015551

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Annexin A2 on lung epithelial cell surface is recognized by severe acute respiratory syndrome-associated coronavirus spike domain 2 antibodies.</title>
<author><name sortKey="Fang, Yi Ting" sort="Fang, Yi Ting" uniqKey="Fang Y" first="Yi-Ting" last="Fang">Yi-Ting Fang</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Basic Medical Sciences, National Cheng Kung University Medical College, Tainan, Taiwan.</nlm:affiliation>
<country xml:lang="fr">Taïwan</country>
<wicri:regionArea>Institute of Basic Medical Sciences, National Cheng Kung University Medical College, Tainan</wicri:regionArea>
<wicri:noRegion>Tainan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lin, Chiou Feng" sort="Lin, Chiou Feng" uniqKey="Lin C" first="Chiou-Feng" last="Lin">Chiou-Feng Lin</name>
</author>
<author><name sortKey="Liao, Pao Chi" sort="Liao, Pao Chi" uniqKey="Liao P" first="Pao-Chi" last="Liao">Pao-Chi Liao</name>
</author>
<author><name sortKey="Kuo, Yu Min" sort="Kuo, Yu Min" uniqKey="Kuo Y" first="Yu-Min" last="Kuo">Yu-Min Kuo</name>
</author>
<author><name sortKey="Wang, Shuying" sort="Wang, Shuying" uniqKey="Wang S" first="Shuying" last="Wang">Shuying Wang</name>
</author>
<author><name sortKey="Yeh, Trai Ming" sort="Yeh, Trai Ming" uniqKey="Yeh T" first="Trai-Ming" last="Yeh">Trai-Ming Yeh</name>
</author>
<author><name sortKey="Shieh, Chi Chang K" sort="Shieh, Chi Chang K" uniqKey="Shieh C" first="Chi-Chang K" last="Shieh">Chi-Chang K. Shieh</name>
</author>
<author><name sortKey="Su, Ih Jen" sort="Su, Ih Jen" uniqKey="Su I" first="Ih-Jen" last="Su">Ih-Jen Su</name>
</author>
<author><name sortKey="Lei, Huan Yao" sort="Lei, Huan Yao" uniqKey="Lei H" first="Huan-Yao" last="Lei">Huan-Yao Lei</name>
</author>
<author><name sortKey="Lin, Yee Shin" sort="Lin, Yee Shin" uniqKey="Lin Y" first="Yee-Shin" last="Lin">Yee-Shin Lin</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2010">2010</date>
<idno type="RBID">pubmed:20015551</idno>
<idno type="pmid">20015551</idno>
<idno type="doi">10.1016/j.molimm.2009.11.019</idno>
<idno type="wicri:Area/PubMed/Corpus">001780</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001780</idno>
<idno type="wicri:Area/PubMed/Curation">001780</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001780</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001714</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001714</idno>
<idno type="wicri:Area/Ncbi/Merge">002048</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Annexin A2 on lung epithelial cell surface is recognized by severe acute respiratory syndrome-associated coronavirus spike domain 2 antibodies.</title>
<author><name sortKey="Fang, Yi Ting" sort="Fang, Yi Ting" uniqKey="Fang Y" first="Yi-Ting" last="Fang">Yi-Ting Fang</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Basic Medical Sciences, National Cheng Kung University Medical College, Tainan, Taiwan.</nlm:affiliation>
<country xml:lang="fr">Taïwan</country>
<wicri:regionArea>Institute of Basic Medical Sciences, National Cheng Kung University Medical College, Tainan</wicri:regionArea>
<wicri:noRegion>Tainan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lin, Chiou Feng" sort="Lin, Chiou Feng" uniqKey="Lin C" first="Chiou-Feng" last="Lin">Chiou-Feng Lin</name>
</author>
<author><name sortKey="Liao, Pao Chi" sort="Liao, Pao Chi" uniqKey="Liao P" first="Pao-Chi" last="Liao">Pao-Chi Liao</name>
</author>
<author><name sortKey="Kuo, Yu Min" sort="Kuo, Yu Min" uniqKey="Kuo Y" first="Yu-Min" last="Kuo">Yu-Min Kuo</name>
</author>
<author><name sortKey="Wang, Shuying" sort="Wang, Shuying" uniqKey="Wang S" first="Shuying" last="Wang">Shuying Wang</name>
</author>
<author><name sortKey="Yeh, Trai Ming" sort="Yeh, Trai Ming" uniqKey="Yeh T" first="Trai-Ming" last="Yeh">Trai-Ming Yeh</name>
</author>
<author><name sortKey="Shieh, Chi Chang K" sort="Shieh, Chi Chang K" uniqKey="Shieh C" first="Chi-Chang K" last="Shieh">Chi-Chang K. Shieh</name>
</author>
<author><name sortKey="Su, Ih Jen" sort="Su, Ih Jen" uniqKey="Su I" first="Ih-Jen" last="Su">Ih-Jen Su</name>
</author>
<author><name sortKey="Lei, Huan Yao" sort="Lei, Huan Yao" uniqKey="Lei H" first="Huan-Yao" last="Lei">Huan-Yao Lei</name>
</author>
<author><name sortKey="Lin, Yee Shin" sort="Lin, Yee Shin" uniqKey="Lin Y" first="Yee-Shin" last="Lin">Yee-Shin Lin</name>
</author>
</analytic>
<series><title level="j">Molecular immunology</title>
<idno type="eISSN">1872-9142</idno>
<imprint><date when="2010" type="published">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Annexin A2 (immunology)</term>
<term>Antibodies, Viral (immunology)</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Autoantigens (immunology)</term>
<term>Cell Line, Tumor</term>
<term>Cross Reactions (immunology)</term>
<term>Epithelial Cells (immunology)</term>
<term>Epithelial Cells (pathology)</term>
<term>Epithelial Cells (virology)</term>
<term>Humans</term>
<term>Interferon-gamma (pharmacology)</term>
<term>Interleukin-6 (pharmacology)</term>
<term>Membrane Glycoproteins (immunology)</term>
<term>Protein Structure, Tertiary</term>
<term>Respiratory Mucosa (immunology)</term>
<term>Respiratory Mucosa (pathology)</term>
<term>Respiratory Mucosa (virology)</term>
<term>SARS Virus (immunology)</term>
<term>Severe Acute Respiratory Syndrome (immunology)</term>
<term>Severe Acute Respiratory Syndrome (pathology)</term>
<term>Severe Acute Respiratory Syndrome (virology)</term>
<term>Spike Glycoprotein, Coronavirus</term>
<term>Up-Regulation (drug effects)</term>
<term>Up-Regulation (immunology)</term>
<term>Viral Envelope Proteins (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Annexine A2 (immunologie)</term>
<term>Anticorps antiviraux (immunologie)</term>
<term>Antiviraux (pharmacologie)</term>
<term>Autoantigènes (immunologie)</term>
<term>Cellules épithéliales (anatomopathologie)</term>
<term>Cellules épithéliales (immunologie)</term>
<term>Cellules épithéliales (virologie)</term>
<term>Glycoprotéine de spicule des coronavirus</term>
<term>Glycoprotéines membranaires (immunologie)</term>
<term>Humains</term>
<term>Interféron gamma (pharmacologie)</term>
<term>Interleukine-6 (pharmacologie)</term>
<term>Lignée cellulaire tumorale</term>
<term>Muqueuse respiratoire (anatomopathologie)</term>
<term>Muqueuse respiratoire (immunologie)</term>
<term>Muqueuse respiratoire (virologie)</term>
<term>Protéines de l'enveloppe virale (immunologie)</term>
<term>Réactions croisées (immunologie)</term>
<term>Régulation positive ()</term>
<term>Régulation positive (immunologie)</term>
<term>Structure tertiaire des protéines</term>
<term>Syndrome respiratoire aigu sévère (anatomopathologie)</term>
<term>Syndrome respiratoire aigu sévère (immunologie)</term>
<term>Syndrome respiratoire aigu sévère (virologie)</term>
<term>Virus du SRAS (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Annexin A2</term>
<term>Antibodies, Viral</term>
<term>Autoantigens</term>
<term>Membrane Glycoproteins</term>
<term>Viral Envelope Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term>
<term>Interferon-gamma</term>
<term>Interleukin-6</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Cellules épithéliales</term>
<term>Muqueuse respiratoire</term>
<term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Up-Regulation</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Annexine A2</term>
<term>Anticorps antiviraux</term>
<term>Autoantigènes</term>
<term>Cellules épithéliales</term>
<term>Glycoprotéines membranaires</term>
<term>Muqueuse respiratoire</term>
<term>Protéines de l'enveloppe virale</term>
<term>Réactions croisées</term>
<term>Régulation positive</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Cross Reactions</term>
<term>Epithelial Cells</term>
<term>Respiratory Mucosa</term>
<term>SARS Virus</term>
<term>Severe Acute Respiratory Syndrome</term>
<term>Up-Regulation</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Epithelial Cells</term>
<term>Respiratory Mucosa</term>
<term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term>
<term>Interféron gamma</term>
<term>Interleukine-6</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Cellules épithéliales</term>
<term>Muqueuse respiratoire</term>
<term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Epithelial Cells</term>
<term>Respiratory Mucosa</term>
<term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Cell Line, Tumor</term>
<term>Humans</term>
<term>Protein Structure, Tertiary</term>
<term>Spike Glycoprotein, Coronavirus</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Glycoprotéine de spicule des coronavirus</term>
<term>Humains</term>
<term>Lignée cellulaire tumorale</term>
<term>Régulation positive</term>
<term>Structure tertiaire des protéines</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infection causes lung failure characterized by atypical pneumonia. We previously showed that antibodies against SARS-CoV spike domain 2 (S2) in the patient sera can cross-react with human lung epithelial cells; however, the autoantigen is not yet identified. In this study, we performed proteomic studies and identified several candidate autoantigens recognized by SARS patient sera in human lung type II epithelial cell A549. Among the candidate proteins, annexin A2, which was identified by mass spectrometry analysis and had the highest score by Mascot data search, was further characterized and investigated for its role as an autoantigen. By confocal microscopic observation, SARS patient sera and anti-S2 antibodies were co-localized on A549 cells and both of them were co-localized with anti-annexin A2 antibodies. Anti-annexin A2 antibodies bound to purified S2 proteins, and anti-S2 bound to immunoprecipitated annexin A2 from A549 cell lysate in a dose-dependent manner. Furthermore, an increased surface expression and raft-structure distribution of annexin A2 was present in A549 cells after stimulation with SARS-induced cytokines interleukin-6 and interferon-gamma. Cytokine stimulation increased the binding capability of anti-S2 antibodies to human lung epithelial cells. Together, the upregulated expression of annexin A2 by SARS-associated cytokines and the cross-reactivity of anti-SARS-CoV S2 antibodies to annexin A2 may have implications in SARS disease pathogenesis.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20015551</PMID>
<DateCompleted><Year>2010</Year>
<Month>02</Month>
<Day>23</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>07</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-9142</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>47</Volume>
<Issue>5</Issue>
<PubDate><Year>2010</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
<Title>Molecular immunology</Title>
<ISOAbbreviation>Mol. Immunol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Annexin A2 on lung epithelial cell surface is recognized by severe acute respiratory syndrome-associated coronavirus spike domain 2 antibodies.</ArticleTitle>
<Pagination><MedlinePgn>1000-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.molimm.2009.11.019</ELocationID>
<Abstract><AbstractText>Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infection causes lung failure characterized by atypical pneumonia. We previously showed that antibodies against SARS-CoV spike domain 2 (S2) in the patient sera can cross-react with human lung epithelial cells; however, the autoantigen is not yet identified. In this study, we performed proteomic studies and identified several candidate autoantigens recognized by SARS patient sera in human lung type II epithelial cell A549. Among the candidate proteins, annexin A2, which was identified by mass spectrometry analysis and had the highest score by Mascot data search, was further characterized and investigated for its role as an autoantigen. By confocal microscopic observation, SARS patient sera and anti-S2 antibodies were co-localized on A549 cells and both of them were co-localized with anti-annexin A2 antibodies. Anti-annexin A2 antibodies bound to purified S2 proteins, and anti-S2 bound to immunoprecipitated annexin A2 from A549 cell lysate in a dose-dependent manner. Furthermore, an increased surface expression and raft-structure distribution of annexin A2 was present in A549 cells after stimulation with SARS-induced cytokines interleukin-6 and interferon-gamma. Cytokine stimulation increased the binding capability of anti-S2 antibodies to human lung epithelial cells. Together, the upregulated expression of annexin A2 by SARS-associated cytokines and the cross-reactivity of anti-SARS-CoV S2 antibodies to annexin A2 may have implications in SARS disease pathogenesis.</AbstractText>
<CopyrightInformation>(c) 2009 Elsevier Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fang</LastName>
<ForeName>Yi-Ting</ForeName>
<Initials>YT</Initials>
<AffiliationInfo><Affiliation>Institute of Basic Medical Sciences, National Cheng Kung University Medical College, Tainan, Taiwan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lin</LastName>
<ForeName>Chiou-Feng</ForeName>
<Initials>CF</Initials>
</Author>
<Author ValidYN="Y"><LastName>Liao</LastName>
<ForeName>Pao-Chi</ForeName>
<Initials>PC</Initials>
</Author>
<Author ValidYN="Y"><LastName>Kuo</LastName>
<ForeName>Yu-Min</ForeName>
<Initials>YM</Initials>
</Author>
<Author ValidYN="Y"><LastName>Wang</LastName>
<ForeName>Shuying</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y"><LastName>Yeh</LastName>
<ForeName>Trai-Ming</ForeName>
<Initials>TM</Initials>
</Author>
<Author ValidYN="Y"><LastName>Shieh</LastName>
<ForeName>Chi-Chang K</ForeName>
<Initials>CC</Initials>
</Author>
<Author ValidYN="Y"><LastName>Su</LastName>
<ForeName>Ih-Jen</ForeName>
<Initials>IJ</Initials>
</Author>
<Author ValidYN="Y"><LastName>Lei</LastName>
<ForeName>Huan-Yao</ForeName>
<Initials>HY</Initials>
</Author>
<Author ValidYN="Y"><LastName>Lin</LastName>
<ForeName>Yee-Shin</ForeName>
<Initials>YS</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2009</Year>
<Month>12</Month>
<Day>16</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Mol Immunol</MedlineTA>
<NlmUniqueID>7905289</NlmUniqueID>
<ISSNLinking>0161-5890</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C472822">ANXA2 protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017306">Annexin A2</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001324">Autoantigens</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C508600">IL6 protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>82115-62-6</RegistryNumber>
<NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D017306" MajorTopicYN="N">Annexin A2</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001324" MajorTopicYN="N">Autoantigens</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003429" MajorTopicYN="N">Cross Reactions</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004847" MajorTopicYN="N">Epithelial Cells</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020545" MajorTopicYN="N">Respiratory Mucosa</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year>
<Month>10</Month>
<Day>08</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2009</Year>
<Month>11</Month>
<Day>07</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2009</Year>
<Month>11</Month>
<Day>13</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2009</Year>
<Month>12</Month>
<Day>18</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2009</Year>
<Month>12</Month>
<Day>18</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2010</Year>
<Month>2</Month>
<Day>24</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">20015551</ArticleId>
<ArticleId IdType="pii">S0161-5890(09)00846-3</ArticleId>
<ArticleId IdType="doi">10.1016/j.molimm.2009.11.019</ArticleId>
<ArticleId IdType="pmc">PMC7112629</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Autoimmun. 2008 Feb-Mar;30(1-2):74-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18171610</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antivir Ther. 2007;12(7):1107-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18018769</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Gen Virol. 2007 Jan;88(Pt 1):19-27</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17170432</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Blood. 2006 Jun 1;107(11):4375-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16493010</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Immunol Rev. 1999 Jun;169:241-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10450521</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virology. 2007 Sep 1;365(2):324-35</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17490702</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Mol Biol Cell. 2004 Jun;15(6):2863-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15064349</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Pathol. 2006 Nov;210(3):288-97</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17031779</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Autoimmunity. 2005 Dec;38(8):559-65</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16390809</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2008 Mar 20;26(13):1644-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18289745</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet. 2003 Jul 26;362(9380):263-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12892955</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Am J Respir Crit Care Med. 2005 Apr 15;171(8):850-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15657466</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Emerg Infect Dis. 2005 Jul;11(7):1016-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16022774</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2005 Feb 18;327(3):900-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15649430</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Clin Invest. 2003 Jun;111(11):1605-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12782660</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Med Virol. 2005 Feb;75(2):185-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15602737</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2004 Mar 19;315(4):1134-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14985131</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Proteome Res. 2005 Nov-Dec;4(6):2435-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16335998</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Viral Immunol. 2006 Summer;19(2):127-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16817755</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Biomed Sci. 2003 Nov-Dec;10(6 Pt 2):664-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14631105</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Neth J Med. 2003 Jul;61(7):238-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14567520</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Mol Immunol. 2008 Feb;45(4):868-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17905435</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Respirology. 2003 Nov;8 Suppl:S25-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15018130</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Respirology. 2003 Nov;8 Suppl:S6-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15018126</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet. 2003 May 24;361(9371):1767-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12781535</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet Infect Dis. 2005 Mar;5(3):147-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15766649</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Eur J Clin Microbiol Infect Dis. 2005 Sep;24(9):583-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16172857</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 1991 Apr;65(4):1789-95</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1848306</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2008 Feb 6;26(6):797-808</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18191004</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Curr Opin Investig Drugs. 2004 Feb;5(2):179-85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15043392</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proteomics. 2005 Mar;5(4):1062-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15682465</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2005 Jun;79(12):7819-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15919935</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Autoimmun. 2010 Feb;34(1):38-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19716269</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Mol Immunol. 2004 Feb;40(14-15):1113-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15036917</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Exp Med. 2005 Aug 1;202(3):415-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16043521</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Infect Chemother. 2004 Feb;10(1):1-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14991510</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Curr Opin Rheumatol. 2007 Nov;19(6):636-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17917546</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1967-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12690091</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Rev Med Virol. 2002 Mar-Apr;12(2):107-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11921306</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9824-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11504947</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Cell Biol. 2000 Sep 4;150(5):1113-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10973999</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Biol Chem. 2000 May 19;275(20):15541-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10809787</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antivir Chem Chemother. 2005;16(1):13-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15739618</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virus Res. 2008 Apr;133(1):13-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17374415</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Immunol. 2004 Jun 15;172(12):7841-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15187168</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Science. 2004 Feb 13;303(5660):944-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14963300</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2006 Mar;80(6):2694-704</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16501079</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2007 Apr 20;25(16):3038-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17289225</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Pathology. 2003 Dec;35(6):526-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14660106</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Med Virol. 2005 Sep;77(1):1-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16032747</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Clin Exp Immunol. 2005 Sep;141(3):500-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16045740</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Rev Immunol. 2005 Dec;5(12):917-27</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16322745</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lupus. 2008 Oct;17(10):943-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18827060</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2004 Nov 12;324(2):773-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15474494</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Biol Chem. 2003 Dec 12;278(50):50338-45</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14522961</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Immunol. 1993 Sep 15;151(6):3381-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8397257</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Curr Opin Immunol. 2005 Aug;17(4):404-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15950449</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Arthritis Rheum. 2007 Aug;56(8):2687-97</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17665396</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Rev Microbiol. 2009 Jun;7(6):439-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19430490</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2007 Aug 10;25(32):6070-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17629360</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Front Biosci. 2002 Feb 01;7:d341-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11815288</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Am J Pathol. 2007 Apr;170(4):1136-47</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17392154</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Eur J Immunol. 2001 May;31(5):1447-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11465101</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Blood. 2005 Mar 1;105(5):1964-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15471954</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Science. 2003 May 30;300(5624):1394-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12730500</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Clin Immunol. 2008 Jul;28(4):291-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18322784</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Immunol. 2001 Mar;2(3):185-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11224510</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Arthritis Rheum. 2008 Sep;58(9):2835-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18759277</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Curr Pharm Des. 2007;13(35):3568-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18220793</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virology. 2005 Mar 30;334(1):134-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15749129</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Biomed Biotechnol. 2008;2008:326464</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18320019</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet. 2003 May 24;361(9371):1773-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12781536</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Pathol. 2006 Jan;208(2):142-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16362992</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Clin Exp Immunol. 2004 Apr;136(1):95-103</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15030519</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet. 2003 May 10;361(9369):1615-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12747883</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Science. 2003 May 30;300(5624):1399-404</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12730501</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet. 2003 Apr 19;361(9366):1319-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12711465</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2008 Nov 25;26(50):6338-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18824060</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Taïwan</li>
</country>
</list>
<tree><noCountry><name sortKey="Kuo, Yu Min" sort="Kuo, Yu Min" uniqKey="Kuo Y" first="Yu-Min" last="Kuo">Yu-Min Kuo</name>
<name sortKey="Lei, Huan Yao" sort="Lei, Huan Yao" uniqKey="Lei H" first="Huan-Yao" last="Lei">Huan-Yao Lei</name>
<name sortKey="Liao, Pao Chi" sort="Liao, Pao Chi" uniqKey="Liao P" first="Pao-Chi" last="Liao">Pao-Chi Liao</name>
<name sortKey="Lin, Chiou Feng" sort="Lin, Chiou Feng" uniqKey="Lin C" first="Chiou-Feng" last="Lin">Chiou-Feng Lin</name>
<name sortKey="Lin, Yee Shin" sort="Lin, Yee Shin" uniqKey="Lin Y" first="Yee-Shin" last="Lin">Yee-Shin Lin</name>
<name sortKey="Shieh, Chi Chang K" sort="Shieh, Chi Chang K" uniqKey="Shieh C" first="Chi-Chang K" last="Shieh">Chi-Chang K. Shieh</name>
<name sortKey="Su, Ih Jen" sort="Su, Ih Jen" uniqKey="Su I" first="Ih-Jen" last="Su">Ih-Jen Su</name>
<name sortKey="Wang, Shuying" sort="Wang, Shuying" uniqKey="Wang S" first="Shuying" last="Wang">Shuying Wang</name>
<name sortKey="Yeh, Trai Ming" sort="Yeh, Trai Ming" uniqKey="Yeh T" first="Trai-Ming" last="Yeh">Trai-Ming Yeh</name>
</noCountry>
<country name="Taïwan"><noRegion><name sortKey="Fang, Yi Ting" sort="Fang, Yi Ting" uniqKey="Fang Y" first="Yi-Ting" last="Fang">Yi-Ting Fang</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Ncbi/Merge

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002048 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 002048 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    Ncbi
   |étape=   Merge
   |type=    RBID
   |clé=     pubmed:20015551
   |texte=   Annexin A2 on lung epithelial cell surface is recognized by severe acute respiratory syndrome-associated coronavirus spike domain 2 antibodies.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i   -Sk "pubmed:20015551" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Annexin A2 on lung epithelial cell surface is recognized by severe acute respiratory syndrome-associated coronavirus spike domain 2 antibodies.

Annexin A2 on lung epithelial cell surface is recognized by severe acute respiratory syndrome-associated coronavirus spike domain 2 antibodies.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki